EGFR and neoplasm: Receptors in tumor cells (e.g., transferrin [Tf] receptor, folate receptor, lectins, and epidermal growth factor receptor [EGFR]) or on the tumoral endothelium (e.g., VEGF receptors, αvβ3 integrin, vascular cell adhesion molecule-1 [VCAM-1] and matrix metalloproteinases [MMPs]) can be targets of ligand-tethered nanosystems [27].